sp Deschner

Document Sample
sp Deschner Powered By Docstoc
					                                                         Leserservice Nr. 18/2008, S. 28 - 40




Liteaturverzeichnis




Zähne und Allgemeingesundheit
Wechselwirkungen zwischen Parodontitiden und Diabetes
James Deschner, Søren Jepsen




1. Micheelis W, Schiffner U. (Gesamtbearbeitung): Vierte Deutsche Mundgesund-heitsstudie
(DMS IV). Neue Ergebnisse zu oralen Erkrankungsprävalenzen, Risikogruppen und zum
zahnärztlichen Ver-sorgungs-grad in Deutschland 2005. Deutscher Ärzte-Verlag, Köln 2006.

2. Micheelis W, Hoffmann T, Holtfreter B, Kocher T, Schroeder E. Zur epidemiologischen
Einschätzung der Parodontitislast in Deutschland – Versuch einer Bilanzierung. DZZ 2008;
63: 464-472

3. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and
projections for 2030. Diabetes Care 2004; 27: 2568-2569.

4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for
the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-1053.

5. Deschner J, Jepsen S. Diabetes mellitus in der Parodontologie. Zahnmedizin up2date 2008;
1: 13-28.

6. Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction.
Periodontol 2000 1997; 14: 9-11.

7. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of
current work. Lab Invest 1976; 34: 235-249.

8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes

9. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining
the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and
HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.
10. Brückel J, Kerner W. Definition, Klassifikation und Diagnostik des Diabetes mellitus.
Diabetologie 2006; 1 Suppl 2: S177-S180.

11. Lalla E, Cheng B, Lal S, Kaplan S, Softness B, Greenberg E, Goland R, Lamster IB.
Diabetes mellitus promotes periodontal destruction in children. J Clin Periodontol 2007; 34:
294-298.

12. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal
disease in the US adult population. Community Dent Oral Epidemiol 2002; 30: 182–192.

13. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, Norderyd OM,
Genco RJ. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J
Periodontol 1994; 65: 260-267.

14. Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent
diabetes mellitus. J Periodontol 1991: 62: 123–130.
15. Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ, Knowler WC.
Periodontal disease and NIDDM in Pima Indians. Diabetes Care 1990; 13: 836-840.

16. Khader YS, Dauod AS, El-Qaderi SS, Alkafajei A, Batayha WQ. Periodontal status of
diabetics compared with nondiabetics: a meta-analysis. J Diabetes Complications 2006; 20:
59-68.

17. Salvi GE, Carollo B, Lang NP. Effects of diabetes mellitus on periodontal and peri-
implant conditions. J Clin Periodontol 2008; 35 (in press).

18. Mattout C, Bourgeois D, Bouchard P. Type 2 diabetes and periodontal indicators:
epidemiology in France 2002-2003. J Periodontal Res 2006; 41: 253-258.

19. Salvi GE, Kandylaki M, Troendle A, Persson GR, Lang NP. Experimental gingivitis in
type 1 diabetics. A controlled clinical and microbiological study. J Clin Periodontol 2005; 32:
310-316.

20. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ.
Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J
Periodontol 1998; 69: 76-83.

21. Soskolne WA, Klinger A. The relationship between periodontal diseases and diabetes: An
overview. Ann Periodontol 2001; 6: 91-98.

22. Lalla E, Cheng B, Lal S, Kaplan S, Softness B, Greenberg E, Goland R, Lamster I.
Diabetes-related parameters and periodontal conditions in children. J Periodontal Res 2007;
42: 345-349.

23. Lim LP, Tay FB, Sum CF, Thai AC. Relationship between markers of glycemic control
and inflammation on severity of periodontal disease in patients with diabetes mellitus. J Clin
Periodontol 2007; 34: 118-123.

24. Guzman S, Karima M, Wang HY, Van Dyke TE. Association between interleukin-1
genotype and periodontal disease in a diabetic population. J Periodontol 2003; 74: 1183–
1190.
25. Tervonen T, Karjalainen K, Knuuttila M, Huumonen S. Alveolar bone loss in type 2
diabetic subjects. J Clin Periodontol 2000; 27: 567–571.

26. Tervonen T, Oliver RC. Long-term control of diabetes mellitus and periodontitis. J Clin
Periodontol 1993; 20: 431–435.

27. Ervasti T, Knuuttila M, Pohjamo L, Haukipuro K. Relation between control of diabetes
mellitus and gingival bleeding. J Periodontol 1985; 56: 154–157.

28. Firatli E. The relationship between clinical periodontal status and insulin-dependent
diabetes mellitus. Results after 5 years. J Periodontol 1997; 68: 136-140.

29. Firatli E, Yilmaz O, Onan U. The relationship between clinical attachment loss and the
duration of the insulin-dependent diabetes mellitus (IDDM) in children and adolescents. J
Clin Periodontol 1996; 23: 362-366.
30. Hugoson A, Thorstensson H, Falk H, Kuylenstierna J. Periodontal conditions in insulin-
dependent diabetics. J Clin Periodontol 1989; 16: 215–223.

31. Moore PA, Weyant RJ, Mongelluzzo MB, Myers DE, Rossie K, Guggenheimer J, Block
HM, Hubar H, Orchard T. Type 1 diabetes mellitus and oral health: Assessment of
periodontal disease. J Periodontol 1999; 70: 409–417.

32. Karjalainen KM, Knuuttila ML, von Dickhoff KJ. Association of the severity of
periodontal disease with organ complications in type 1 diabetic patients. J Periodontol 1994;
65: 1067–1072.

33. Bacic M, Plancak D, Granic M. CPITN assessment of periodontal status in diabetics. J
Periodontol 1988; 59: 816–822.

34. Rosenthal IM, Abrams H, Kopczyk A. The relationship of inflammatory periodontal
disease to diabetic status in insulin-dependent diabetes mellitus patients. J Clin Periodontol
1988; 15: 425-429.

35. Rylander H, Ramberg P, Blohme G, Lindhe J. Prevalence of periodontal disease in young
diabetics. J Clin Periodontol 1987; 14: 38–43.

36. Shultis WA, Weil EJ, Looker HC, Curtis JM, Shlossman M, Genco RJ, Knowler WC,
Nelson RG. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2
diabetes. Diabetes Care 2007; 30: 306-311.

37. Saremi A, Nelson RG, Tulloch-Reid M, Hanson RL, Sievers ML, Taylor GW, Shlossman
M, Bennett PH, Genco R, Knowler WC. Periodontal disease and mortality in type 2 diabetes.
Diabetes Care 2005; 28: 27-32.

38. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ.
Severe periodontitis and risk for poor glycemic control in patients with non-insulin dependent
diabetes mellitus. J Periodontol 1996; 67: 1085–1093.
39. Thorstensson H, Kuylenstierna J, Hugoson A. Medical status and complications in
relation to periodontal disease experience in insulin-dependent diabetics. J Clin Periodontol
1996; 23: 194–202.

40. Lalla E, Kaplan S, Yang J, Roth GA, Papapanou PN, Greenberg S. Effects of periodontal
therapy on serum C-reactive protein, sE-selectin and tumor necrosis factor-alpha secretion by
peripheral blood-derived macrophages in diabetes a pilot study. J Periodontal Res 2007; 42:
274-282.

41. Navarro-Sanchez AB, Faria-Almeida R, Bascones-Martinez A. Effect of non-surgical
periodontal therapy on clinical and immunological response and glycaemic control in type 2
diabetic patients with moderate periodontitis. J Clin Periodontol 2007; 34: 835-843.

42. Kiran M, Arpak N, Unsal E, Erdogan MF. The effect of improved periodontal health on
metabolic control in type 2 diabetes mellitus. J Clin Periodontol 2005; 32: 266–272.

43. Llambés F, Silvestre FJ, Hernandez-Mijares A, Guiha R, Caffesse R. Effect of non-
surgical periodontal treatment with or without doxycycline on the periodontium of type 1
diabetic patients. J Clin Periodontol 2005; 32: 915-920.
44. Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanavasita W. The effect of
periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. Oral Diseases
2005; 11: 293-298.
45. Martorelli de Lima AF, Cury CC, Palioto DB, Duro AM, Carvahlo da Silva R, Wolff LF.
Therapy with adjunctive doxycycline local delivery in patients with type 1 diabetes mellitus
and periodontitis. J Clin Periodontol 2004; 31: 648-653.
46. Skaleric U, Schara R, Medvescek M, Hanlon A, Doherty F, Lessem J. Periodontal
treatment by Arestin and its effects on glycemic control in type 1 diabetic patients. J Int Acad
Periodontol 2004; 6, 160-165.
47. Rodrigues DC, Taba Jr M, Novaes Jr AB, Souza SLS, Grisi MFM. Effect of non-surgical
periodontal therapy on glycemic control in patients with type 2 diabetes mellitus. J
Periodontol 2003; 74: 1361-1367.
48. Al-Mubarak S, Ciancio S, Aljada A, Mohanty P, Ross C, Dandona P. Comparative
evaluation of adjunctive oral irrigation in diabetics. J Clin Periodontol 2002; 29: 295-300.
49. Rocha M, Nava LE, de la Torre CV, Sanchez-Marin F, Garay-Sevilla ME, Malacara JM.
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes
mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;
72: 204-209.
50. Christgau M, Palitzsch KD, Schmalz G, Kreiner U, Frenzel S. Healing response to non-
surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and
immunological results. J Clin Periodontol 1998: 25: 112–124.
51. Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ.
Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol
1997; 68: 713-719.
52. Faria-Almeida R, Navarro A, Bascones A. Clinical and metabolic changes after
conventional treatment of type 2 diabetic patients with chronic periodontitis. J Periodontol
2006; 77: 591-598.
53. Westfelt E, Rylander H, Blohmé G, Jonasson P, Lindhe J. The effects of periodontal
therapy in diabetics. Results after 5 years. J Clin Periodontol 1996; 23: 92-100.
54. Tervonen T, Karjalainen K. Periodontal disease related to diabetic status. A pilot study of
the response to periodontal therapy in type 1 diabetes. J Clin Periodontol 1997; 24: 505-510.
55. O'Connell PA, Taba M, Nomizo A, Foss Freitas MC, Suaid FA, Uyemura SA,Trevisan
GL, Novaes AB, Souza SL, Palioto DB, Grisi MF. Effects of periodontal therapy on glycemic
control and inflammatory markers. J Periodontol 2008; 79: 774-783.
56. Sbordone L, Ramaglia L, Barone A, Ciaglia RN, Tenore A, Iacono VJ. Periodontal status
and selected cultivable anaerobic microflora of insulin-dependent juvenile diabetics. J
Periodontol 1995; 66: 452-461.
57. Sastrowijoto SH, Hillemans P, van Steenbergen TJ, Abraham-Inpijn L, de Graaff J.
Periodontal condition and microbiology of healthy and diseased periodontal pockets in type 1
diabetes mellitus patients. J Clin Periodontol 1989; 16: 316-322.
58. Mealey BL, Oates TW; American Academy of Periodontology. Diabetes mellitus and
periodontal diseases. J Periodontol 2006; 77: 1289-1303.
59. Schmidt AM, Weidman E, Lalla E, Yan SD, Hori O, Cao R, Brett JG, Lamster IB.
Advanced glycation endproducts (AGEs) induce oxidant stress in the gingiva: a potential
mechanism underlying accelerated periodontal disease associated with diabetes. J Periodont
Res 1996; 31: 508-515.
60. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular
system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64: 459-470.
61. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking
in diabetes: a puzzle nearing resolution. Diabetes 1996; 45 Suppl 3: S67-72.
62. Mott JD, Khalifah RG, Nagase H, Shield CF 3rd, Hudson JK, Hudson BG. Nonenzymatic
glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;
52: 1302-1312.
63. Shinoda Y. Immunohistochemical localization of type IV collagen and laminin in the
gingival capillary basement membrane of the diabetic rat. J Osaka Dent Univ 1992; 26: 49-66.
64. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern
DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D’Agati V, Schmidt AM. Blockade of receptor
for advanced glycation endproducts: a new target for therapeutic intervention in diabetic
complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-88.
65. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and
IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;
240: 1546-1548.
66. Wautier JL, Wautier MP. Blood cells and vascular cell interactions in diabetes. Clin
Hemorheol Microcirc 2001; 25: 49-53.
67. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern
D. Advanced glycation endproducts interacting with their endothelial receptor induce
expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial
cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin
Invest 1995; 96: 1395-1403.
68. Nah SS, Choi IY, Yoo B, Kim YG, Moon HB, Lee CK. Advanced glycation end products
increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic
chondrocytes. FEBS Lett 2007; 581: 1928-1932.
69. Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT. Advanced
glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast
apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem 2005; 280: 12087-
12095.
70. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM,
Schmidt AM. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic
mice. J Clin Invest 2000; 105: 1117–1124.
71. Lalla E, Lamster IB, Feit M, Huang L, Schmidt AM. A murine model of accelerated
periodontal disease in diabetes. J Periodontal Res 1998; 33: 387-399.
72. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM,
Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptor for advanced glycation end-
products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513–525.
73. Preshaw PM, Foster N, Taylor JJ. Cross-susceptibility between periodontal disease and
type 2 diabetes mellitus: an immunobiological perspective. Periodontol 2000 2007; 45: 138-
157.
74. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A.
Macrophages in human visceral adipose tissue: increased accumulation in obesity and a
source of resistin and visfatin. Diabetologia 2006: 49: 744–747.
75. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with
potent proinflammatory properties. J Immunol 2005; 174: 5789–5795.
76. Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates proliferation
and activation of human circulating monocytes. Cell Immunol 1999; 194: 6–11.
77. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and
tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes
1996; 45: 954–959.
78. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced
glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci
1995; 748: 562–570.
79. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis
factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
80. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and
interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta
Diabetol 1999; 36: 67-72.
81. Duarte PM, de Oliveira MCG, Tambeli CH, Parada CA, Casati MZ, Nociti Jr FH.
Overexpression of interleukin-1b and interleukin-6 may play an important role in periodontal
breakdown in type 2 diabetic patients. J Periodontal Res 2007; 42: 377-381.
82. Salvi GE, Yalda B, Collins JG, Jones BH, Smith FW, Arnold RR, Offenbacher S.
Inflammatory mediator response as a potential risk marker for periodontal diseases in
insulindependent diabetes mellitus populations. J Periodontol 1997; 68: 127–135.
83. Ficara AJ, Levin MP, Grower MF, Kramer GD. A comparison of the glucose and protein
content of gingival fluid from diabetics and nondiabetics. J Periodontal Res 1975; 10: 171-
175.
84. Takai N, Shinohara M, Yoshida Y, Ohura K, Mori M, Kakudo Y. Effect of streptozotocin
diabetes on gingivitis in plaque-susceptible rats. J Dent Res 1986; 65: 49-52.
85. McNamara TF, Ramamurthy NS, Mulvihill JE, Golub LM. The development of an altered
gingival crevicular microflora in the alloxan-diabetic rat. Arch Oral Biol 1982; 27: 217-223.
86. Ebersole JL, Holt SC, Hansard R, Novak MJ. Microbiologic and immunologic
characteristics of periodontal disease in Hispanic americans with type 2 diabetes. J
Periodontol 2008; 79: 637-646.
87. Hintao J, Teanpaisan R, Chongsuvivatwong V, Ratarasan C, Dahlen G. The
microbiological profiles of saliva, supragingival and subgingival plaque and dental caries in
adults with and without type 2 diabetes mellitus. Oral Microbiol Immunol 2007; 22: 175-181.
88. Zambon JJ, Reynolds H, Fisher JG, Shlossman M, Dunford R, Genco RJ. Microbiological
and immunological studies of adult periodontitis in patients with noninsulin-dependent
diabetes mellitus. J Periodontol 1988; 59: 23-31.
89. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between
periodontal infections and systemic disease. Clin Microbiol Infect 2007; 13 Suppl 4: 3-10.
90. Jansson H, Lindholm E, Lindh C, Groop L, Bratthall G. Type 2 diabetes and risk for
periodontal disease: a role for dental health awareness. J Clin Periodontol 2006; 33: 408-414.
91. Aldridge JP, Lester V, Watts TLP, Collins A, Viberti G, Wilson RF. Single-blind studies
of the effects of improved periodontal health on metabolic control in Type 1 diabetes mellitus.
J Clin Periodontol 1995; 22: 271–275.
92. Iwamoto Y, Nishimura F, Nakagawa M, Sugimoto H, Shikata K, Makino H, Fukuda
T,Tsuji T, Iwamoto M, Murayama Y. The effect of antimicrobial periodontal treatment on
circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2
diabetes. J Periodontol 2001; 72: 774-778.
93. Stewart JE, Wager KA, Friedlander AH, et al. The effect of periodontal treatment on
glycaemic control in patients with type 2 diabetes mellitus. J Clin Periodontol 2001; 28: 306-
310.
94. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment
improve glycemic control in diabetic patients? A meta-analysis of intervention studies. J Dent
Res 2005; 84: 1154-1159.
95. Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, Christiansen CL,
Rothendler JA, Garcia RI. Does periodontal care improve glycemic control? The department
of veterans affairs dental diabetes study. J Clin Periodontol 2007; 34: 46-52.
96. Williams RC, Barnett AH, Claffey N, Davis M, Gadsby R, Kellett M, Lip GY, Thackray
S. The potential impact of periodontal disease on general health: a consensus view. Curr Med
Res Opin 2008; 24: 1635-1643.
97. Geerts SO, Nys M, De MP, Charpentier J, Albert A, Legrand V, Rompen EH. Systemic
release of endotoxins induced by gentle mastication: association with periodontitis severity. J
Periodontol 2002; 73: 73-78.
98. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-
reactive protein in relation to periodontitis. J Clin Periodontol 2008; 35: 277-290.
99. Bretz WA, Weyant RJ, Corby PM, Ren D, Weissfeld L, Kritchevsky SB, Harris T,
Kurella M, Satterfield S, Visser M, Newman AB. Systemic inflammatory markers,
periodontal diseases, and periodontal infections in an elderly population. J Am Geriatr Soc
2005; 53: 1532-1537.
100. Loos BG. Systemic markers of inflammation in periodontitis. J Periodontol 2005; 76(11
Suppl): 2106-2115.
101. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation
of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis
patients. J Periodontol 2000; 71: 1528-1534.
102. Mathur A, Michalowicz B, Castillo M, Aeppli D. Interleukin-1 alpha, interleukin-8 and
interferon-alpha levels in gingival crevicular fluid. J Periodontal Res 1996; 31: 489-495.
103. Preiss DS, Meyle J. Interleukin-1 beta concentration of gingival crevicular fluid. J
Periodontol 1994; 65: 423-428.
104. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone
resorptive cytokines in periodontal disease. J Periodontol 1991; 62: 504-509.
105. Hönig J, Rordorf-Adam C, Siegmund C, Wiedemann W, Erard F. Increased interleukin-1
beta (IL-1 beta) concentration in gingival tissue from periodontitis patients. J Periodontal Res
1989; 24: 362-367.
106. D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive
periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res 2005; 84:
269-273.
107. D’Aiuto F, Parkar M, Andreou G, Suvan J, Brett PM, Ready D, Tonetti MS.
Periodontitis and systemic inflammation: control of the local infection is associated with a
reduction in serum inflammatory markers. J Dent Res 2004: 83: 156–160.
108. Iwamoto Y, Nishimura F, Soga Y, Takeuchi K, Kurihara M, Takashiba S, Murayama Y.
Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis
factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol
2003; 74: 1231-1236.
109. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin
signaling through IRS-1 phosphorylation. Biochimie 2005; 87: 99-109.
110. Tzeng TF, Liu IM, Cheng JT. Activation of opioid mu-receptors by loperamide to
improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells.
Diabetologia 2005; 48: 1386-1392.
111. De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces
insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-
dependent manner. J Biol Chem 2004; 279: 17070-17078.
112. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6
(IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte:
prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372–379.
113. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1
adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells
from insulin-resistant subjects. J Biol Chem 2003; 278: 45777–45784.
114. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase
activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.
J Clin Invest 1994a; 94: 1543–1549.
115. Hotamisligil GS, Murray DL, Choy LN. Tumor necrosis factor alpha inhibits signaling
from the insulin receptor. Proc Natl Acad Sci USA 1994b; 91: 4854–4858.
116. Youngren JF. Regulation of insulin receptor function. Cell Mol Life Sci 2007; 64: 873-
891.
117. Janket SJ, Jones JA, Meurman JH, Baird AE, Van Dyke TE. Oral infection,
hyperglycemia, and endothelial dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 2008; 105: 173-179.
118. Sheiham A, Steele JG, Marcenes W, Lowe C, Finch S, Bates CJ, Prentice A, Walls AW.
The relationship among dental status, nutrient intake, and nutritional status in older people. J
Dent Res 2001; 80: 408-413.
119. Ryan ME. Diagnostic & therapeutic strategies for the management of the diabetic
patient. Compend Contin Educ Dent 2008; 29: 32-38, 40-44.
120. Rees TD. Periodontal management of the patient with diabetes mellitus. Periodontol
2000 2000; 23: 63-72.
121. Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care
1993; 16: 329-334.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:24
posted:7/28/2011
language:German
pages:8